Literature DB >> 15726649

G to A hypermutation of hepatitis B virus.

Chiemi Noguchi1, Hiromi Ishino, Masataka Tsuge, Yoshifumi Fujimoto, Michio Imamura, Shoichi Takahashi, Kazuaki Chayama.   

Abstract

G to A hypermutation of the human immunodeficiency virus type 1 (HIV-1) is induced by a deaminase APOBEC3G and is related to host antiviral defense. APOBEC3G has also been found to reduce the replication of HIV-1 by an unknown mechanism. This enzyme also reduces the production of hepatitis B virus, although the mechanism for this action has not been clearly elucidated. The hypermutated hepatitis B virus (HBV) is rarely found in usual sequencing analyses. Using peptide nucleic acid mediated by polymerase chain reaction clamping, we detected the hypermutated HBV DNA in 1 of 8 patients with acute HBV infection and 4 of 10 with chronic HBV infection. In the latter group, hypermutated genomes were found only in eAb-positive patients. As much as 72.5% of G residues were mutated in the hypermutated clones. G to A substitutions were predominant in almost all clones sequenced compared with other substitutions. G to A mutated viral genomes also were found in HepG2-derived cell lines that continuously produced HBV into the supernatant. Both alpha and gamma interferon reduced virus production in these cell lines, but they did not alter the frequency of the hypermutation. Transcripts of APOBEC3G, as well as some other deaminases, were found in these cell lines. In conclusion, our results show that part of the minus strand DNA of HBV is hypermutated both in vitro (HepG2 cell lines) and in vivo. The role and mechanism of hypermutation in reducing HBV replication should be further investigated to understand the anti-HBV defense system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726649     DOI: 10.1002/hep.20580

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  67 in total

1.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 2.  APOBEC family proteins: novel antiviral innate immunity.

Authors:  Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

Review 4.  Powerful mutators lurking in the genome.

Authors:  Vincent Petit; Jean-Pierre Vartanian; Simon Wain-Hobson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-03-12       Impact factor: 6.237

Review 5.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

Review 6.  The current structural and functional understanding of APOBEC deaminases.

Authors:  Ronda Bransteitter; Courtney Prochnow; Xiaojiang S Chen
Journal:  Cell Mol Life Sci       Date:  2009-06-23       Impact factor: 9.261

Review 7.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

8.  Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.

Authors:  Lindi Tan; Phuong Thi Nguyen Sarkis; Tao Wang; Chunjuan Tian; Xiao-Fang Yu
Journal:  FASEB J       Date:  2008-09-30       Impact factor: 5.191

9.  A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.

Authors:  Anjie Zhen; Tao Wang; Ke Zhao; Yong Xiong; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

10.  Human APOBEC1 cytidine deaminase edits HBV DNA.

Authors:  Minerva Cervantes Gonzalez; Rodolphe Suspène; Michel Henry; Denise Guétard; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  Retrovirology       Date:  2009-10-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.